Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Read More

Sitting Down with Percival Barretto-Ko

An Interview with Astellas Americas President, Percival Barretto-Ko Read More

WiserCare Announcement

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making

Prograf News

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients Read More

An interview with Astellas' Kevin Brown

When Employee Resource Groups Intersect Read More

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Read More

https://newsroom.astellas.us/2019-03-28-Astellas-Five-Consecutive-Years-of-Perfect-Equality-Scores

Astellas: Five Consecutive Years of Perfect Equality Scores Read More

1

2

3

4

5

6

7

News

Latest

News / Media

Apr 02, 2019

Phase 3 ADMIRAL Trial Data Show XOSPATA^® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia -Study results will be presented at AACR2019-

News / Media

Mar 28, 2019

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - Companies Plan to Submit Biologics License Application Later This Year –

News / Media

Mar 27, 2019

Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO) - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

News / Corporate

Apr 03, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization

News / Corporate

Apr 01, 2019

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy

News / Corporate Awards

Mar 28, 2019

Astellas: Five Consecutive Years of Perfect Equality Scores